WO2006066978A1 - Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics - Google Patents
Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics Download PDFInfo
- Publication number
- WO2006066978A1 WO2006066978A1 PCT/EP2005/014217 EP2005014217W WO2006066978A1 WO 2006066978 A1 WO2006066978 A1 WO 2006066978A1 EP 2005014217 W EP2005014217 W EP 2005014217W WO 2006066978 A1 WO2006066978 A1 WO 2006066978A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- butyl
- terphenyl
- ethyl
- carboxylic acid
- diethylamino
- Prior art date
Links
- BGRALNXNRQTZFW-UHFFFAOYSA-N CCN(C(C)=O)c(cc1)c(C(C)(C)C)cc1-c1c(CCCNC2CC2)ccc(-c(cc2)ccc2C(OCC)=O)c1 Chemical compound CCN(C(C)=O)c(cc1)c(C(C)(C)C)cc1-c1c(CCCNC2CC2)ccc(-c(cc2)ccc2C(OCC)=O)c1 BGRALNXNRQTZFW-UHFFFAOYSA-N 0.000 description 1
- DQIIBGYRWSLFIV-UHFFFAOYSA-N CCN(CC)c(cc1)c(C(C)(C)C)cc1-c1c(CCCNC2CCCCC2)ccc(-c(cc2)ccc2C(O)=O)c1 Chemical compound CCN(CC)c(cc1)c(C(C)(C)C)cc1-c1c(CCCNC2CCCCC2)ccc(-c(cc2)ccc2C(O)=O)c1 DQIIBGYRWSLFIV-UHFFFAOYSA-N 0.000 description 1
- NDZZZIFSCDWRFC-UHFFFAOYSA-N CCOC(c(cc1)ccc1-c(cc1)cc(-c(cc2)cc(C(C)(C)C)c2N2CCCC2)c1OCCO)=O Chemical compound CCOC(c(cc1)ccc1-c(cc1)cc(-c(cc2)cc(C(C)(C)C)c2N2CCCC2)c1OCCO)=O NDZZZIFSCDWRFC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- Novel ligands that modulate RAR receptors and use thereof in human medicine and in cosmetics
- the invention relates to novel compounds as novel and useful industrial products, which are ligands that modulate RAR receptors.
- the invention also relates to compositions containing them, to processes for preparing them and to their use in pharmaceutical compositions for use in human or veterinary medicine, or alternatively in cosmetic compositions, and to the non-therapeutic use of these compositions.
- vitamin A and its derivatives Compounds with activity of retinoid type (vitamin A and its derivatives) are widely described in the literature as having activity in cell proliferation and differentiation processes. These properties give this class of compounds high potential in the treatment or prevention of numerous pathologies, and more particularly in dermatology and cancer. Many biological effects of retinoids are mediated by modulating the nuclear retinoic acid receptors (RAR).
- RAR nuclear retinoic acid receptors
- RAR receptors activate transcription by binding to DNA sequence elements, known as RAR response elements (RARE), in the form of a heterodimer with the retinoid X receptors (known as RXRs).
- RARE RAR response elements
- RAR ⁇ Three subtypes of human RARs have been identified and described: RAR ⁇ , RAR ⁇ and RAR ⁇ .
- patent US 6 150 413 which describes triaromatic compounds
- patent US 6 214 878 which describes stilbene compounds
- patent US 6 218 128, which describes a family of bicyclic or tricyclic molecules.
- the Applicant has invented novel compounds that modulate retinoic acid receptors.
- R 1 is a hydrogen atom, an alkyl radical of 1 to 4 carbon atoms or a -CF 3 radical;
- R 2 is a hydrogen atom, an alkyl or alkoxy radical of 1 to 4 carbon atoms or a chlorine atom;
- R 3 is a hydrogen atom, a linear or branched alkyl or alkoxy radical of 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms optionally substituted with a methoxy group, or alternatively a linear or branched alkyl radical of 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms containing an ether function;
- R 4 is a hydrogen atom or an alkyl radical of 1 to 3 carbon atoms
- R 5 is a hydrogen atom or an alkyl radical of 1 to 3 carbon atoms
- - Y represents two hydrogen atoms or a hetero atom, for instance oxygen or sulfur;
- - Ar represents a 1 ,4-phenyl, 2,5-pyridyl, 5,2-pyridyl or 2,5-thiophenyl ring;
- - X represents an oxygen atom optionally substituted with an alkyl or alkylamine chain or a C-C single bond
- o Q is an oxygen atom or an -NH- bond
- o Re represents a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms, a cycioalkyl radical of 3 to 6 carbon atoms or a -C(O)CH 3 or -C(O)CH 2 CH 3 radical;
- R 7 and R 7 ' represent, independently of each other, a hydrogen atom or a hydroxyl group, on condition that R 7 and R 7 ' are not simultaneously a hydroxyl group;
- o n 0, 1, 2, 3, 4 or 5;
- the compounds according to the invention are in the form of a salt, it is preferably an alkali metal or alkaline-earth metal salt, or alternatively a zinc salt or a salt of an organic amine or of an acidic partner when the compound is itself basic.
- the alkyl radicals of 1 to 3 carbon atoms are preferably chosen from methyl, ethyl, i-propyl and n-propyl radicals.
- the alkyl radicals of 1 to 4 carbon atoms are preferably chosen from methyl, ethyl, i-propyl, i-butyl and t-butyl radicals.
- the alkyl radicals of 1 to 6 carbon atoms are preferably chosen from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl and hexyl.
- the alkyl radicals of 1 to 10 carbon atoms are linear or branched chains preferably chosen from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t- butyl, pentyl, hexyl, heptyl, octyl, nonyl and dodecyl.
- alkoxy radical containing from 1 to 10 carbon atoms means an alkyl radical containing from 1 to 10 carbon atoms linked to the rest of the molecule via an oxygen atom.
- the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy, tert- butoxy and hexyloxy radicals.
- alkoxy radical containing from 1 to 6 carbon atoms means an alkyl radical containing from 1 to 6 carbon atoms linked to the rest of the molecule via an oxygen atom.
- the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy, te/ ⁇ -butoxy and hexyloxy radicals.
- alkoxy radical containing from 1 to 4 carbon atoms means an alkyl radical containing from 1 to 4 carbon atoms linked to the rest of the molecule via an oxygen atom.
- the alkoxy radical is chosen from methoxy, ethoxy, isopropyloxy and terf-butoxy radicals.
- the cycloalkyl radicals of 3 to 6 carbon atoms are preferably chosen from cyclopropyl, cyclopentyl and cyclohexyl.
- the compounds of formula (I) that are more particularly preferred are those for which at least one, and preferably all, of the conditions below are satisfied: - R1 is a hydrogen atom or a t-butyl or i-propyl radical;
- R2 is a hydrogen atom or a t-butyl or i-propyl radical
- R3 is a hydrogen atom or an ethyl radical
- R4 and R5 are, independently of each other, a methyl or ethyl radical or together form a pyrrolidine ring;
- - A is as defined above in which R 6 represents a hydrogen atom, an i-propyl or t-butyl radical, a cycloalkyl radical of 3 to 6 carbon atoms or a -C(O)CH 3 or -C(O)CH 2 CH 3 radical.
- a subject of the present invention is also the processes for preparing the compounds of formula (I), in particular according to the reaction schemes given in Figures 1, 2 and 3.
- the intermediates of general formula 1 or 2 are prepared from the commercial starting material 1.
- Compound 1 is subjected to a first step of esterification of the carboxylic acid function (a), performed under standard esterification conditions including, for example, the methods described in "Protective Groups in Organic Synthesis” by T. W. Greene & P. G. M. Wuts, 3rd edition (J. Wiley & sons), pages 373-377 or in "Comprehensive Organic Transformations” by R.C. Larock, 2 nd edition (J. Wiley & sons), pages 1932-1941.
- a halide bromide or iodide
- a halide bromide or iodide
- standard bromination conditions for example by adding dibromine or an equivalent reagent such as a tetraalkylammonium tribromide
- standard iodination conditions for example sodium iodide and sodium hypochlorite
- the compounds of general formula 3 are then obtained via standard methods of etherification of phenols (c), for instance an etherification similar to a Williamson reaction starting with corresponding alkyl halides in the presence of a base, or alternatively a reaction of Mitsunobu type with the corresponding hydroxyl derivatives (see “Comprehensive Organic Transformations” by R.C. Larock, 2 nd edition (J. Wiley & sons), pages 889-910 or, respectively: a. Dermer, O.C., Chem. Rev. 1934, 14, 409 or Nakatsugi, T. Synthesis, 1987, 280: b. Mitsunobu, O. Synthesis 1981, 1).
- a deprotection step (d) suited to the nature of PG, the description of which will be found in "Protective Groups in Organic Synthesis" by T. W. Greene & P. G. M. Wuts, 3rd edition (J. Wiley & sons) to obtain
- the intermediates of general formula 7 may be obtained from the compounds 6 after a first step of bromination (f) in the para position (see above) followed by alkylation or amidation of the aniline function (g) in the presence, respectively, of a dialkyl sulfate or of an alkyl halide and a base (see, for example, Dehmlow, E.V., Tet. Lett. 1985, 25, 97 or the reference below) or in the presence of an acyl chloride or a corresponding anhydride and a base (for example Et 3 N) in accordance with the methods described, for example, in "Chemistry of the Amino Group" by S. Patai (Wiley-lnterscience, NY 1968) pages 669- 682.
- the compounds 7 may be obtained after bromination of 6 and then formation of the ring (g), for example in the presence of a 1 ,4- dihalobutane or a 1 ,5-dihalopentane or the carbonyl analogues thereof, and of a base, or via a method described in "Chemistry of the Amino Group” by S. Patai (Wiley- lnterscience, NY 1968) pages 669-682.
- the compounds of general formula 7 may also be generated after para- bromination (f, see above) and then formation (h) and reduction (i) of a pyrrolidinone, piperidinone, succinimide or piperidine-2,6-dione group (see, for example, Ohta, S. Heterocycles 1993, 36 (4), 743; Hubbard, J. L.; J. Heterocycl. Chem. 1992, 29 (4), 719; Akula, M. R.; Synth. Commun. 1998, 28 (11), 2063; Collins, C. J. Tetrahedron Lett. 1999, 40 (19), 3673).
- the second reaction is the generation of a boronic acid or boronate function from the bromide group (i), for example by generating an organolithium or organomagnesium reagent trapped with a trialkyl borate (see, for example, Cladingboel, D. E. Org. Process Res. Dev. 2000, 4 (3), 153 or Li, W. J. Org. Chem. 2002, 67 (15), 5394) or alternatively by performing a coupling reaction with bis-dialkoxydiborane or dialkoxyborane in the presence of a catalyst of transition metal type (see, for example, Ishiyama, T. J. Org. Chem. 1995, 60 (23), 7508 or Murata, M., J. Org. Chem. 1997, 62 (19), 6458).
- - Synthesis of the compounds in which X O ( Figure 2)
- the synthesis of the final compounds of general formulae 11 and 12 may be performed according to two parallel routes for which only the order of the reactions changes.
- a first route requires the synthesis of the intermediate 9, via a coupling reaction of Suzuki type 0) between the intermediate 2 and the boronate/boronic acid partner of formula 8, under standard Suzuki coupling conditions (see A. Suzuki et a/., Synth. Commun. 1981, 11, 513 or Sharp, MJ. Tet. Lett. 1985, 26, 5997) or alternatively, where appropriate, optimized conditions (see, for example, Littke, A. F. et a/., J. Am. Chem. Soc. 2000, 122 (17), 4020-4028).
- the compounds 9 are obtained directly when R 3 is other than H, or after a reaction to reveal the carboxylic acid function, for example by using conditions among those described in "Comprehensive Organic Transformations" by R. C. Larock, 2 nd edition (J. Wiley & sons), pages 1959-1968.
- the intermediate 9 may also be subjected to the conditions (c) described above in order to obtain the compounds of general formula 10.
- these same final compounds 11 and 12 may be obtained by subjecting, respectively, the intermediates 4 and 5 to the coupling conditions (j) described above.
- the advanced intermediates 11 and 12 may be subjected to reactions to reveal the carboxylic acid function, for example using conditions among those described in "Comprehensive Organic Transformations” by R.C. Larock, 2 nd edition (J. Wiley & sons), pages 1959-1968.
- the compounds of general formula 13 may be obtained after a sequence of conversion of the primary alcohol function of 11 into an amine, for example via oxidation (k) followed by reductive amination (I) (see, for example, "Comprehensive Organic Transformations” by R.C. Larock, 2 nd edition (J. Wiley & sons)) or alternatively conversion of the alcohol into a halide and substitution of the halogen atom with an amine.
- the intermediates of general formula 9 are first converted into suitable sulfonyl esters under standard conditions, for example into triflates (see, for example, Robl, J. A. Tetrahedron Lett. 1990, 31 (24), 3421) (m), and this group is then subjected to an allylation reaction (n), for example in the presence of tributylallyltin and of a transition metal catalyst, for example tetrakis(triphenylphosphine)palladium (for an example, see Martorell, G.; Garcia-Raso, A.; Saa, J. M.; Tetrahedron Lett. 1990, 31 (16), 2357), to obtain the intermediates of type 14.
- a transition metal catalyst for example tetrakis(triphenylphosphine)palladium
- the final compounds of general formula 15 may then be obtained via an oxidation reaction (o) of the olefin function, for instance an oxidative hydroboration reaction (see, for example, Luo, F. T.; Negishi, E.; J. Org. Chem. 1983, 48, 5144 or "Comprehensive
- the compounds according to the invention have modulatory properties on retinoic acid receptors (RAR). This activity on the RAR ⁇ , ⁇ and v receptors is measured in a transactivation test and quantified by means of the dissociation constant Kdapp (apparent), as described in Example 55.
- the preferred compounds of the present invention have a dissociation constant of less than or equal to 5000 nM, advantageously less than or equal to 1000 nM and preferentially less than or equal to 1 nM.
- the compounds are at least modulators of receptors of RARy type, selectively relative to the subtypes ⁇ and ⁇ , i.e. they have a ratio between the Kdapp for the RAR ⁇ or RAR ⁇ receptors, and the Kdapp for the RARy receptors, of greater than or equal to 5.
- this ratio RAR ⁇ /RAR ⁇ or RARy/RAR ⁇ is greater than or equal to 10, advantageously greater than or equal to 50 and more advantageously greater than or equal to 100.
- a subject of the present invention is also the compounds of formula (I) as described above, as medicaments.
- pigmentation disorders such as hyperpigmentation, melasma, hypopigmentation or vitiligo
- lipid metabolism complaints such as obesity, hyperlipidaemia, or non-insulin-dependent diabetes
- a subject of the present invention is also a pharmaceutical composition
- a pharmaceutical composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) as defined above.
- a subject of the present invention is also a novel medicinal composition intended especially for treating the abovementioned complaints, which is characterized in that it comprises, in a pharmaceutically acceptable support that is compatible with the mode of administration selected for this composition, at least one compound of formula (I), an optical isomer thereof or a salt thereof.
- composition according to the invention may be administered orally, enterally, parenterally, topically or ocularly.
- the pharmaceutical composition is preferably packaged in a form that is suitable for topical application.
- the composition may be in the form of tablets, gel capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, suspensions of microspheres or nanospheres or lipid or polymer vesicles allowing a controlled release.
- the composition may be in the form of solutions or suspensions for infusion or for injection.
- the compounds according to the invention are generally administered at a daily dose of about 0.01 mg/kg to 100 mg/kg of body weight, in one or more dosage intakes.
- the compounds are used systemically, at a concentration generally of between 0.001% and 10% by weight and preferably between 0.01% and 1% by weight, relative to the weight of the composition.
- the pharmaceutical composition according to the invention is more particularly intended for treating the skin and mucous membranes and may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks, pomades, powders, impregnated pads, syndets, solutions, gels, sprays, mousses, suspensions, sticks, shampoos or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or of lipid or polymer vesicles or gelled or polymer patches allowing a controlled release.
- the compounds are used topically at a concentration generally of between 0.001% and 10% by weight and preferably between 0.01% and 1% by weight, relative to the total weight of the composition.
- the compounds of formula (I) according to the invention also find an application in cosmetics, in particular in body and hair hygiene and especially for treating acne-prone skin, for promoting regrowth of the hair or for limiting hair loss, for combating the greasy appearance of the skin or the hair, in protection against the harmful aspects of sunlight or in the treatment of physiologically dry skin, and for preventing and/or combating photoinduced or chronological ageing.
- a subject of the invention is thus also a cosmetic composition
- a cosmetic composition comprising, in a physiologically acceptable support, at least one of the compounds of formula (I).
- a subject of the invention is also the non-therapeutic use of a cosmetic composition comprising at least one compound of formula (I) for preventing and/or treating the signs of ageing and/or dry skin.
- a subject of the invention is also the non-therapeutic use of a cosmetic composition comprising at least one compound of formula (I) for body or hair hygiene.
- the cosmetic composition according to the invention containing, in a physiologically acceptable medium, at least one compound of formula (I) or an optical or geometrical isomer thereof or a salt thereof may be especially in the form of a cream, a milk, a gel, suspensions of microspheres or nanospheres or lipid or polymer vesicles, impregnated pads, solutions, sprays, mousses, sticks, soaps, washing bases or shampoos.
- the concentration of compound of formula (I) in the cosmetic composition is preferably between 0.001 % and 3% by weight, relative to the total weight of the composition.
- physiologically acceptable medium means a medium that is compatible with the skin and optionally with its integuments (eyelashes, nails or hair) and/or mucous membranes.
- compositions as described above may also contain inert additives, or even pharmacodynamically active additives as regards the pharmaceutical compositions, or combinations of these additives, and especially:
- - preserving agents such as para-hydroxybenzoic acid esters; - stabilizers; - moisture regulators;
- antioxidants such as ⁇ -tocopherol, butylhydroxyanisole, butylhydroxytoluene, superoxide dismutase, ubiquinol or certain metal-chelating agents;
- - depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid
- emollients for instance glycerol, PEG 400, thiamorpholinone and its derivatives or urea
- antiseborrhoeic or anti-acne agents such as S-carboxymethylcysteine, S- benzylcysteamine, salts thereof or derivatives thereof, or benzoyl peroxide
- antibiotics for instance erythromycin and its esters, neomycin, clindamycin and its esters, and tetracyclines;
- antifungal agents such as ketoconazole or poly-4,5-methylene-3-isothiazolidones
- agents for promoting regrowth of the hair for instance Minoxidil (2,4-diamino-6- piperidinopyrimidine 3-oxide) and its derivatives, Diazoxide (7-chloro-3-methyl-1 ,2,4- benzothiadiazine 1,1-dioxide) and Phenytoin (5,4-diphenylimidazolidine-2,4-dione); - non-steroidal anti-inflammatory agents;
- ⁇ - ⁇ -hydroxy acids and ⁇ -keto acids or derivatives thereof such as lactic acid, malic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, glyceric acid or ascorbic acid, and also salts, amides or esters thereof, or ⁇ -hydroxy acids or derivatives thereof, such as salicylic acid and its salts, amides or esters;
- - ion-channel blockers such as potassium-channel blockers
- compositions in combination with medicaments known to interfere with the immune system (for example cyclosporin, FK 506, glucocorticoids, monoclonal antibodies, cytokines or growth factors, etc.).
- medicaments known to interfere with the immune system for example cyclosporin, FK 506, glucocorticoids, monoclonal antibodies, cytokines or growth factors, etc.
- a person skilled in the art will take care to select the optional compound(s) to be added to these compositions such that the advantageous properties intrinsically attached to the present invention are not, or are not substantially, adversely affected by the envisaged addition.
- Another subject of the invention relates to a cosmetic process for enhancing the appearance of the skin, characterized in that a composition comprising at least one compound of formula (I) as defined above is applied to the skin.
- Activation of the retinoic acid receptors with the compounds of formula (I) according to the invention makes it possible to obtain skin of enhanced surface appearance.
- the temperature is raised to room temperature and the reaction medium is stirred for 3 hours.
- the reaction medium is cooled again to -7O 0 C and 69 mL of 1M hydrochloric acid solution (69 mmol) are added.
- the temperature is raised to O 0 C and the reaction medium is stirred for 30 minutes.
- the reaction is extracted after addition of 250 mL of water and 250 mL of ethyl acetate.
- aqueous 1 N sodium hydroxide solution 0.9 mL of aqueous 1 N sodium hydroxide solution is added to a solution of 300 mg of ethyl 3"-fert-butyl-4"-diethylamino-4'-(4-hydroxybutoxy)-[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (Example 2b) in a mixture of 10 mL of tetrahydrofuran and 3 mL of water.
- the reaction medium is stirred at room temperature for 12 hours.
- 0.5 mL of aqueous 1N sodium hydroxide solution is then added. After 12 hours at room temperature, the reaction medium is heated to 50 0 C and then left at room temperature for 3 days. The reaction is stopped by adding 5 mL of water.
- Example 1d In a manner similar to that of Example 2a, by reacting 1 g of ethyl 3"-te/f-butyl-4"- diethylamino-4'-hydroxy[1 ,1';3',1"]terphenyl-4-carboxylate (obtained in Example 1d) (2.2 mmol) in 20 mL of dimethylformamide with 880 mg (2.7 mmol) of caesium carbonate and 0.6 mL of 1-bromo-3-(terf-butyldimethylsilanyloxy)propane (2.4 mmol).
- Example 2b In a manner similar to that of Example 2b, by reacting 1 g of ethyl 3"-fert-butyl-4'-[4-(fert- butyldimethylsilanyloxy)propoxy]-4"-diethylamino[1 ,1';3',1"]terphenyl-4-carboxylate (1.62 mmol) in 25 mL of tetrahydrofuran with 2 mL of 1 M tetrabutylammonium fluoride.
- Example 1d In a manner similar to that of Example 1d, by reacting 1 g of ethyl 3'-bromo-4'-[3-(fe/f- butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate (2 mmol) with 580 mg of 4- diethylaminophenylboronic acid (3 mmol) in the presence of tetrakis(triphenylphosphine)- palladium.
- the reaction medium is heated at the reflux temperature of the tetrahydrofuran for 5 hours.
- the reaction medium is concentrated under vacuum.
- Example 2b In a manner similar to that of Example 2b, by reacting 400 mg of ethyl 4'-[4-(tert- butyldimethylsilanyloxy)butoxy]-4"-pyrrolidin-1-yl-3"-trifluoromethyl[1 ,1';3',1"]terphenyl-4- carboxylate (0.6 mmol) with 0.75 ml.
- Example 9b ethyl 3'-bromo-4'-[3-(feAt- butyldimethylsilanyloxy)propoxy]biphenyl-4-carboxylate obtained in Example 9b (1.2 mmol) with 380 mg of 3-tert-butyl-4-pyrrolidinophenylboronic acid (1.5 mmol) obtained in Example 17b in the presence of 1.3 ml.
- Example 13a In a manner similar to that of Example 1d, by reacting 800 mg of ethyl 3'-bromo-4'-(2- acetoxyethoxy)biphenyl-4-carboxylate obtained in Example 13a (2 mmol) with 730 mg of
- Example 14a In a manner similar to that of Example 14a, by reacting 110 mg of ethyl 4'-(2- acetoxyethoxy)-3"-terf-butyl-4"-pyrrolidin-1 -yl[1 , 1 ';3', 1 "]terphenyl-4-carboxylate (0.2 mmol) with 2 ml.
- Example 1d 1.1 g of ethyl 3"-fe/f-butyl-4"-diethyiamino-4'-hydroxy[1,1';3',1"]terphenyl-4-carboxylate obtained in Example 1d (2.5 mmol) are dissolved at room temperature in 22.4 mL of dichloromethane and the temperature of the reaction medium is then lowered to O 0 C; 112 mg of dimethylaminopyridine are added, followed by addition of 0.88 mL of triethylamine (6 mmol) and dropwise addition of 0.5 mL of trifiic anhydride (3 mmol). The temperature is raised to room temperature and the reaction medium is stirred for 20 minutes.
- reaction medium is again reduced to 0 0 C, 52.8 mL of NaOH (53 mmol) are added portionwise, and the medium is stirred for 10 minutes at O 0 C; 37.3 mL of H 2 O 2 (426 mmol) are then added dropwise and the reaction medium is warmed to room temperature and then stirred for 2 hours 30 minutes.
- the reaction is stopped by adding 500 mL of ice- water and then extracted with 500 mL of ethyl acetate.
- the organic phases are washed with 1 L of water and then dried over magnesium sulfate.
- the solvents are evaporated off and the residue is then purified by chromatography on silica gel (eluent: 7/3 heptane/ethyl acetate).
- Example 32b 150 mg of ethyl 3"-feAf-butyl-4"-diethylamino-4 l -vinyl[1,1';3',1"]te ⁇ henyl-4-carboxylate obtained in Example 32b are dissolved in 10 mL of dichloromethane under a nitrogen atmosphere. 45 mg of N-methylmorpholine are added to the reaction medium, and
- the dissolution is performed under cold conditions (0 0 C), and 11.4 mL of trioctylphosphine are then added (26 mmol) followed by addition of a solution of 8.5 g of carbon tetrabromide (26 mmol) dissolved in 10 volumes of Et 2 O added dropwise.
- the reaction medium is stirred at 0°C for 30 minutes and then for 1 hour 30 minutes at room temperature.
- the reaction is stopped by adding 100 mL of water and then extracted with 100 mL of ethyl acetate.
- the organic phases are washed with 400 mL of water and then dried over magnesium sulfate.
- the reaction medium is heated at 100 0 C for 3 hours and is then poured into water beforehand and acidified slightly with a 1 mol/L solution of hydrochloric acid, and extracted twice with ethyl acetate. The organic phases obtained are combined and washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated to give a brownish oil.
- N-(2-tert-Butyl-4-bromophenyl)-4-chlorobutanamide 20 g (0.0877 mol; 1 eq.) of 2-tert-butyl-4-bromoaniline (prepared according to Example 1 a)) are dissolved in 100 ml of dichloromethane at about O 0 C.
- reaction medium is returned to room temperature and stirred for 1 hour 30 minutes. 70 ml of H 2 O are added and the reaction medium is then allowed to settle. The aqueous phase is re-extracted with dichloromethane, and the organic phases are collected and washed successively with aqueous 1M NaHC ⁇ 3 and then with H 2 O.
- reaction medium cooled to room temperature and filtered through a sinter funnel packed with Celite; the filter cake is rinsed thoroughly with ethyl acetate, and H 2 O is added to the filtrate, which is then allowed to settle.
- the organic phase obtained is then concentrated on a rotavapor to give a residue, which is purified by chromatography on silica.
- step d (obtained in step d)) are dissolved in 300 ml of tetrahydrofuran. 10.9 g (0.259 mol; 1.5 eq.) of lithium hydroxide monohydrate as a solution in 70 ml of H 2 O are added at room temperature.
- the reaction medium is refluxed for about 1 hour 30 minutes.
- reaction medium is then cooled to room temperature and dilute hydrochloric acid solution is added (330 ml; ⁇ 1M). 100 ml of H 2 O are added and this suspension is cooled to about 0 0 C; it is maintained at this temperature for about 15 minutes then filtered. After drying, 59 g of a white powder are obtained.
- reaction medium is cooled to room temperature and filtered through a sinter funnel packed with Celite; the filter cake is rinsed thoroughly with ethyl acetate, and H 2 O is added to the filtrate and the phases are allowed to separate by settling.
- [1 ,1 ',3',1"]terphenyl-4-benzoate are dissolved in 10 ml of absolute ethanol.
- 312 mg (7.8 mmol; 4.5 eq.) of sodium hydroxide and 4 ml of H 2 O are added at room temperature and the mixture is then heated to reflux. These conditions are maintained for about 1 hour 30 minutes.
- the reaction medium is concentrated to a small volume; H 2 O is added to the precipitate formed, and the mixture is then acidified with acetic acid to pH ⁇ 4-5.
- This suspension is fluidized by adding H 2 O and stirred at room temperature for 1 hour.
- the resulting mixture is filtered through a sinter funnel, rinsed with H 2 O until the filtrate is neutral, and oven-dried.
- the activation of receptors with an agonist (activator) in HeLa cells leads to the expression of a reporter gene, luciferase, which, in the presence of a substrate, generates light.
- the activation of the receptors may thus be measured by quantifying the luminescence produced after incubating the cells in the presence of a reference agonist.
- the inhibitory products displace the agonist from its site, thus preventing activation of the receptor.
- the activity is measured by quantifying the reduction in light produced. This measurement makes it possible to determine the inhibitory activity of the compounds according to the invention.
- KdApp Kd apparent
- the HeLa cell lines used are stable transfectants containing the plasmids ERE- ⁇ Glob- Luc-SV-Neo (reporter gene) and RAR ( ⁇ , ⁇ , ⁇ ) ER-DBD-puro. These cells are inoculated into 96-well plates at a rate of 10 000 cells per well in 100 ⁇ l of DMEM medium without phenol red, and supplemented with 10% defatted calf serum. The plates are then incubated at 37°C and 7% CO 2 for 4 hours.
- test products of the reference ligand (4-[2-(5, 5,8,8- tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)propenyl]benzoic acid), of the 100% control (100 nM 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)propenyl]benzoic acid) and of the 0% control (500 nM 4- ⁇ (E)-3-[4-(4-tert-butylphenyl)-5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-2-naphthyl]-3-oxopropenyl ⁇ benzoic acid) are added at a rate of 5 ⁇ l per well. The plates are then incubated for 18 hours at 37°C and 7% CO 2 .
- the culture medium is removed by turning over and 100 ⁇ l of a 1 :1 PBS/luciferine mixture is added to each well. After 5 minutes, the plates are read using the luminescence reader.
- This example illustrates various concrete formulations based on the compounds according to the invention.
- Liquid petroleum jelly oil 9.10O g
- Silicone oil (“Abil 300 000 cSt” sold by Goldschmidt) qs 100 g
- Glyceryl monostearate 2.500 g
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL05824484T PL1831149T3 (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics |
ES05824484T ES2380777T3 (en) | 2004-12-23 | 2005-12-21 | New ligands that modulate RAR receptors and their use in human medicine and cosmetics |
AU2005318292A AU2005318292B2 (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics |
DK05824484.9T DK1831149T3 (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate scar receptors and their use in human medicine and cosmetics |
SI200531509T SI1831149T1 (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics |
MX2007007696A MX2007007696A (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics. |
JP2007547399A JP5258299B2 (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate RAR receptors and their use in human pharmaceuticals and cosmetics |
CN2005800447781A CN101087752B (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics |
KR1020077014372A KR101316992B1 (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics |
CA2590246A CA2590246C (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics |
BRPI0517500A BRPI0517500B8 (en) | 2004-12-23 | 2005-12-21 | compound, use of a composition, pharmaceutical composition, cosmetic composition, non-therapeutic uses of a cosmetic composition, and cosmetic process to improve the appearance of the skin |
EP05824484A EP1831149B1 (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics |
AT05824484T ATE542791T1 (en) | 2004-12-23 | 2005-12-21 | NEW LIGANDS AS RAR RECEPTOR MODULATORS AND THEIR USE IN HUMAN MEDICINE AND COSMETICS |
US11/819,068 US7807708B2 (en) | 2004-12-23 | 2007-06-25 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
US12/842,347 US8227507B2 (en) | 2004-12-23 | 2010-07-23 | Ligands that modulate RAR receptors |
US13/527,299 US8470871B2 (en) | 2004-12-23 | 2012-06-19 | Ligands that modulate RAR receptors |
NL301042C NL301042I2 (en) | 2004-12-23 | 2020-06-10 | Trifarotene, optionally in the form of a pharmaceutically acceptable salt |
LTPA2022002C LTC1831149I2 (en) | 2004-12-23 | 2022-03-10 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0413848A FR2880020B1 (en) | 2004-12-23 | 2004-12-23 | NEW MODULATORY LIGANDS OF RAR RECEPTORS, USE IN HUMAN MEDICINE AND COSMETICS |
FR04/13848 | 2004-12-23 | ||
US64738305P | 2005-01-28 | 2005-01-28 | |
US60/647,383 | 2005-01-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/819,068 Continuation US7807708B2 (en) | 2004-12-23 | 2007-06-25 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006066978A1 true WO2006066978A1 (en) | 2006-06-29 |
Family
ID=35981712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/014217 WO2006066978A1 (en) | 2004-12-23 | 2005-12-21 | Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1831149B1 (en) |
JP (1) | JP5258299B2 (en) |
KR (1) | KR101316992B1 (en) |
AU (1) | AU2005318292B2 (en) |
BR (1) | BRPI0517500B8 (en) |
CA (1) | CA2590246C (en) |
CY (1) | CY1112721T1 (en) |
MX (1) | MX2007007696A (en) |
NL (1) | NL301042I2 (en) |
PL (1) | PL1831149T3 (en) |
WO (1) | WO2006066978A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009067600A2 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating inflammation |
WO2009156675A2 (en) | 2008-05-30 | 2009-12-30 | Galderma Research & Development | Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative and a retinoid |
US20100143445A1 (en) * | 2007-05-04 | 2010-06-10 | Galderma Research & Development | Dermatological/cosmetic skin depigmenting compositions |
WO2010119992A1 (en) | 2009-04-16 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes |
WO2011012897A1 (en) | 2009-07-31 | 2011-02-03 | Astrazeneca Ab | New combinations for the treatment of asthma |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
WO2012085583A1 (en) | 2010-12-23 | 2012-06-28 | Astrazeneca Ab | New compound |
WO2012085582A1 (en) | 2010-12-23 | 2012-06-28 | Astrazeneca Ab | Compound |
WO2013178745A1 (en) * | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Aqueous-gel-type topical compositions in the form of a homogenous suspension of an active principle of the class of retinoids containing at least one hydrophobic silica |
WO2013178758A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | O/w-emulsion-type topical pharmaceutical compositions containing a retinoid |
WO2013178760A1 (en) * | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Oil/water-emulsion-type topical compositions containing a retinoid |
WO2013178759A1 (en) * | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Topical compositions in the form of a gel containing a particular solubilised retinoid |
WO2013178756A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Dermatological composition including oleosomes and retinoids, method for preparing same and use thereof |
WO2013178749A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing same, method of producing same and use thereof in dermatology |
WO2013178743A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Microcapsules containing retinoids, method for preparing same, and pharmaceutical compositions containing same |
WO2013178752A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Method for preparing a dermatological composition including oleosomes |
US8791267B2 (en) | 2007-11-21 | 2014-07-29 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders |
WO2015082659A1 (en) * | 2013-12-04 | 2015-06-11 | Galderma Research & Development | Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology |
FR3028763A1 (en) * | 2014-11-20 | 2016-05-27 | Galderma Sa | COMPOSITIONS COMPRISING A COMPOUND OF THE AVERMECTIN FAMILY AND AN ANTAGONIST COMPOUND OF AT LEAST ONE OF THE RAR RECEPTORS FOR THE TREATMENT OF ACNE |
US20180185329A1 (en) * | 2015-06-23 | 2018-07-05 | Galderma Research & Development | Compositions comprising water dispersible nanoparticles of a retinoid compound |
US20180325859A1 (en) * | 2014-11-20 | 2018-11-15 | Galderma Sa | Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne |
RU2677885C2 (en) * | 2013-05-10 | 2019-01-22 | Басф Се | Products with high content of uv stabilizers |
WO2021064072A1 (en) | 2019-10-02 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve |
WO2021119351A1 (en) | 2019-12-11 | 2021-06-17 | Taro Pharmaceutical Industries Ltd. | Preparation of trifarotene and intermediates and polymorphs thereof |
US11197831B2 (en) | 2015-05-29 | 2021-12-14 | Galderma Research And Development | Compositions comprising at least one dispersed active principle and lipid microcapsules |
CN113999117A (en) * | 2021-09-10 | 2022-02-01 | 南京迈诺威医药科技有限公司 | Preparation method of biphenyl compound |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8623871B2 (en) | 2006-01-25 | 2014-01-07 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
US9084778B2 (en) | 2012-06-01 | 2015-07-21 | Galderma Research & Development | Topical compositions containing a retinoid of the oil-in-water emulsion type |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999010308A1 (en) * | 1997-08-21 | 1999-03-04 | Galderma Research & Development | Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same |
US6150413A (en) * | 1997-05-23 | 2000-11-21 | Centre International De Recherches Dermatologiques | Triaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9604926D0 (en) * | 1996-03-08 | 1996-05-08 | Sandoz Ltd | Organic compounds |
FR2759292B1 (en) * | 1997-02-10 | 2000-08-11 | Cird Galderma | USE OF RETINOIDS AS PIGMENTATION INDUCING AGENTS |
-
2005
- 2005-12-21 KR KR1020077014372A patent/KR101316992B1/en active Protection Beyond IP Right Term
- 2005-12-21 BR BRPI0517500A patent/BRPI0517500B8/en active IP Right Grant
- 2005-12-21 WO PCT/EP2005/014217 patent/WO2006066978A1/en active Application Filing
- 2005-12-21 MX MX2007007696A patent/MX2007007696A/en active IP Right Grant
- 2005-12-21 AU AU2005318292A patent/AU2005318292B2/en active Active
- 2005-12-21 CA CA2590246A patent/CA2590246C/en not_active Expired - Fee Related
- 2005-12-21 PL PL05824484T patent/PL1831149T3/en unknown
- 2005-12-21 JP JP2007547399A patent/JP5258299B2/en active Active
- 2005-12-21 EP EP05824484A patent/EP1831149B1/en active Active
-
2012
- 2012-04-25 CY CY20121100388T patent/CY1112721T1/en unknown
-
2020
- 2020-06-10 NL NL301042C patent/NL301042I2/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150413A (en) * | 1997-05-23 | 2000-11-21 | Centre International De Recherches Dermatologiques | Triaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof |
WO1999010308A1 (en) * | 1997-08-21 | 1999-03-04 | Galderma Research & Development | Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100143445A1 (en) * | 2007-05-04 | 2010-06-10 | Galderma Research & Development | Dermatological/cosmetic skin depigmenting compositions |
US8791267B2 (en) | 2007-11-21 | 2014-07-29 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders |
WO2009067600A3 (en) * | 2007-11-21 | 2009-07-30 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating inflammation |
WO2009067600A2 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating inflammation |
WO2009156675A2 (en) | 2008-05-30 | 2009-12-30 | Galderma Research & Development | Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative and a retinoid |
WO2010119992A1 (en) | 2009-04-16 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes |
WO2011012897A1 (en) | 2009-07-31 | 2011-02-03 | Astrazeneca Ab | New combinations for the treatment of asthma |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
WO2012085583A1 (en) | 2010-12-23 | 2012-06-28 | Astrazeneca Ab | New compound |
WO2012085582A1 (en) | 2010-12-23 | 2012-06-28 | Astrazeneca Ab | Compound |
US9498465B2 (en) | 2012-06-01 | 2016-11-22 | Galderma Research & Development | Topical compositions in the form of a gel containing a particular solubilized retinoid |
CN104507469B (en) * | 2012-06-01 | 2018-01-02 | 盖尔德马研究及发展公司 | Oil-in-water emulsion type topical composition containing biostearin |
WO2013178759A1 (en) * | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Topical compositions in the form of a gel containing a particular solubilised retinoid |
WO2013178756A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Dermatological composition including oleosomes and retinoids, method for preparing same and use thereof |
WO2013178749A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing same, method of producing same and use thereof in dermatology |
WO2013178743A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Microcapsules containing retinoids, method for preparing same, and pharmaceutical compositions containing same |
WO2013178752A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Method for preparing a dermatological composition including oleosomes |
FR2991178A1 (en) * | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | AQUEOUS GEL-LIKE TOPICAL COMPOSITIONS IN THE FORM OF A HOMOGENEOUS SUSPENSION OF AN ACTIVE PRINCIPLE OF THE RETINOID CLASS CONTAINING AT LEAST ONE HYDROPHOBIC SILICA. |
FR2991175A1 (en) * | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | TOPICAL PHARMACEUTICAL COMPOSITIONS OF O / W EMULSION TYPE CONTAINING RETINOID |
FR2991172A1 (en) * | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING MICROCAPSULES |
FR2991177A1 (en) * | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | TOPICAL COMPOSITIONS, CONTAINING RETINOID, EMULSION TYPE EMULSION IN WATER WITHOUT EMULSIFIER |
FR2991176A1 (en) * | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | TOPICAL COMPOSITIONS CONTAINING SOLUBILIZED RETINOID OF HYDROGLYCOLIC GEL TYPE |
FR2991174A1 (en) * | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | DERMATOLOGICAL COMPOSITION COMPRISING OLEOSOMES AND RETINOIDS, PROCESS FOR PREPARING SAME AND USE THEREOF |
WO2013178758A1 (en) | 2012-06-01 | 2013-12-05 | Galderma Research & Development | O/w-emulsion-type topical pharmaceutical compositions containing a retinoid |
CN104507469A (en) * | 2012-06-01 | 2015-04-08 | 盖尔德马研究及发展公司 | Oil/water-emulsion-type topical compositions containing a retinoid |
US20150125520A1 (en) * | 2012-06-01 | 2015-05-07 | Galderma Research & Development | Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing the same, process for preparing the same and use thereof in dermatology |
EP4169512A1 (en) * | 2012-06-01 | 2023-04-26 | Galderma Research & Development | Dermatological composition comprising oleosomes and retinoids, method for preparing same and use thereof |
EP2854803B2 (en) † | 2012-06-01 | 2022-08-24 | Galderma Research & Development | Topical gel composition comprising a solubilized specific retinoid |
US9375477B2 (en) | 2012-06-01 | 2016-06-28 | Galderma Research & Development | Topical compositions of aqueous gel type in the form of a homogeneous suspension of an active principle of the retinoid class containing at least one hydrophobic silica |
WO2013178745A1 (en) * | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Aqueous-gel-type topical compositions in the form of a homogenous suspension of an active principle of the class of retinoids containing at least one hydrophobic silica |
AU2013269582B2 (en) * | 2012-06-01 | 2017-08-10 | Galderma Research & Development | Topical compositions in the form of a gel containing a particular solubilised retinoid |
AU2013269583B2 (en) * | 2012-06-01 | 2017-08-24 | Galderma Research & Development | Oil/water-emulsion-type topical compositions containing a retinoid |
RU2637408C2 (en) * | 2012-06-01 | 2017-12-04 | Галдерма Ресерч Энд Девелопмент | Retinoid-containing compounds for local application of "oil in water" emulsion type |
WO2013178760A1 (en) * | 2012-06-01 | 2013-12-05 | Galderma Research & Development | Oil/water-emulsion-type topical compositions containing a retinoid |
US9855244B2 (en) | 2012-06-01 | 2018-01-02 | Galderma Research & Development | O/W-emulsion-type topical pharmaceutical compositions containing a retinoid |
AU2013269581B2 (en) * | 2012-06-01 | 2018-03-01 | Galderma Research & Development | O/W-emulsion-type topical pharmaceutical compositions containing a retinoid |
RU2655305C2 (en) * | 2012-06-01 | 2018-05-24 | Галдерма Ресерч Энд Девелопмент | Oil-in-water emulsion-type topical pharmaceutical compositions containing retinoid |
EP2854803B1 (en) | 2012-06-01 | 2018-06-27 | Galderma Research & Development | Topical gel composition comprising a solubilized specific retinoid |
US10702604B2 (en) | 2012-06-01 | 2020-07-07 | Galderma Research & Development | Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing the same, process for preparing the same and use thereof in dermatology |
RU2677885C2 (en) * | 2013-05-10 | 2019-01-22 | Басф Се | Products with high content of uv stabilizers |
US10772807B2 (en) | 2013-12-04 | 2020-09-15 | Galderma Research & Development | Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use of same in dermatology |
US10857080B2 (en) | 2013-12-04 | 2020-12-08 | Galderma Research & Development | Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics |
CN113559083A (en) * | 2013-12-04 | 2021-10-29 | 盖尔德马研究及发展公司 | Lipid microcapsules comprising a retinoid |
WO2015082659A1 (en) * | 2013-12-04 | 2015-06-11 | Galderma Research & Development | Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology |
FR3028763A1 (en) * | 2014-11-20 | 2016-05-27 | Galderma Sa | COMPOSITIONS COMPRISING A COMPOUND OF THE AVERMECTIN FAMILY AND AN ANTAGONIST COMPOUND OF AT LEAST ONE OF THE RAR RECEPTORS FOR THE TREATMENT OF ACNE |
US10653659B2 (en) | 2014-11-20 | 2020-05-19 | Galderma S.A. | Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne |
US20180325859A1 (en) * | 2014-11-20 | 2018-11-15 | Galderma Sa | Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne |
US11197831B2 (en) | 2015-05-29 | 2021-12-14 | Galderma Research And Development | Compositions comprising at least one dispersed active principle and lipid microcapsules |
US20180185329A1 (en) * | 2015-06-23 | 2018-07-05 | Galderma Research & Development | Compositions comprising water dispersible nanoparticles of a retinoid compound |
US10925855B2 (en) * | 2015-06-23 | 2021-02-23 | Galderma Research & Development | Compositions comprising water dispersible nanoparticles of a retinoid compound |
WO2021064072A1 (en) | 2019-10-02 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve |
WO2021119351A1 (en) | 2019-12-11 | 2021-06-17 | Taro Pharmaceutical Industries Ltd. | Preparation of trifarotene and intermediates and polymorphs thereof |
CN114787129A (en) * | 2019-12-11 | 2022-07-22 | 塔罗制药工业有限公司 | Preparation of trefarosin and intermediates and polymorphs thereof |
AU2020402049B2 (en) * | 2019-12-11 | 2023-06-01 | Taro Pharmaceutical Industries Ltd. | Preparation of Trifarotene and intermediates and polymorphs thereof |
US11691946B2 (en) | 2019-12-11 | 2023-07-04 | Taro Pharmaceutical Industries Ltd. | Preparation of Trifarotene and intermediates and polymorphs thereof |
CN113999117A (en) * | 2021-09-10 | 2022-02-01 | 南京迈诺威医药科技有限公司 | Preparation method of biphenyl compound |
CN113999117B (en) * | 2021-09-10 | 2023-12-08 | 南京迈诺威医药科技有限公司 | Preparation method of biphenyl compound |
Also Published As
Publication number | Publication date |
---|---|
BRPI0517500B1 (en) | 2018-10-09 |
CA2590246A1 (en) | 2006-06-29 |
BRPI0517500B8 (en) | 2021-05-25 |
EP1831149A1 (en) | 2007-09-12 |
EP1831149B1 (en) | 2012-01-25 |
JP5258299B2 (en) | 2013-08-07 |
AU2005318292A1 (en) | 2006-06-29 |
BRPI0517500A (en) | 2008-10-07 |
PL1831149T3 (en) | 2012-06-29 |
NL301042I1 (en) | 2020-06-17 |
CY1112721T1 (en) | 2016-02-10 |
RU2007127867A (en) | 2009-01-27 |
KR101316992B1 (en) | 2013-10-11 |
RU2440973C2 (en) | 2012-01-27 |
MX2007007696A (en) | 2007-08-17 |
JP2008525364A (en) | 2008-07-17 |
CA2590246C (en) | 2015-07-14 |
KR20070087626A (en) | 2007-08-28 |
AU2005318292B2 (en) | 2011-09-22 |
NL301042I2 (en) | 2020-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1831149B1 (en) | Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics | |
US8470871B2 (en) | Ligands that modulate RAR receptors | |
US7348449B2 (en) | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | |
US20070021473A1 (en) | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | |
US7439396B2 (en) | Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors | |
ES2357193T3 (en) | NEW LEGAND AGONISTS OF RAR RECEPTORS, USED IN HUMAN MEDICINE AND ALSO IN COSMETICS. | |
MXPA04011972A (en) | Novel ligands that are inhibitors of the rar receptors, process for preparing them and use thereof in human medicine and in cosmetics. | |
EP1694627A2 (en) | Novel ligands that are activators of the rar receptors, use in human medicine and in cosmetics | |
US7326803B2 (en) | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005824484 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005318292 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2590246 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007547399 Country of ref document: JP Ref document number: MX/a/2007/007696 Country of ref document: MX Ref document number: 1020077014372 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580044778.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005318292 Country of ref document: AU Date of ref document: 20051221 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5201/DELNP/2007 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005318292 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/05930 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007127867 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005824484 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0517500 Country of ref document: BR |